Geography axis: coverage anchored in Latin America. Pair with exactly one subject category (Pharma, Policy & Markets, Digital Health, Medical Devices or a Therapy Area). Country, company and regulator go in tags.
Brazil’s securities regulator has ordered a tender offer for Oncoclínicas shares, with analysts estimating the total outlay at R$ 12–14 billion — roughly double initial projections — as a parallel …
Ecuador’s Sercop signed 114 medication supply agreements in May–June 2026, but 71 carry no purchase orders as of mid-August — leaving contracted suppliers unpaid and public hospital shelves empty.
Brazil’s Conselho Federal de Medicina activated Resolution 2.454/2026 on August 26, imposing immediate ethical sanctions on physicians and institutions deploying AI without governance frameworks.
Clinics across four Patagonian provinces suspended all PAMI patient care for 24 hours, citing a 143% tariff adjustment against 341% cumulative inflation — a gap that may signal broader provider …
Brazilian startup PoliHealth is integrating genetic, laboratory, and lifestyle data into a single AI platform for clinicians, targeting R$8 million in revenue and 30,000 health professional users within three years.
Anvisa cancelled Elevidys’s conditional registration on August 24 at Roche’s request, citing insufficient safety and efficacy data — ending Brazilian access to the country’s most expensive approved drug.
Anvisa has approved datopotamab deruxtecan (Datroway) for adults with advanced EGFR-mutated non-small cell lung cancer in Brazil, expanding targeted therapy options in one of oncology’s most active segments.
PASSUS IPS, a Colombian healthcare provider, has warned it may suspend services due to unpaid debts from EPS insurers, exposing a structural financing gap in Colombia’s health system.
Brazil’s health regulator has approved five new semaglutide injection pens for diabetes treatment, intensifying competition against Novo Nordisk as the molecule’s patent expired in March 2026.
Anvisa has granted Eurofarma the first generic registration for the dapagliflozin-metformin fixed-dose combination, mandating a minimum 35% price discount versus AstraZeneca’s Xigduo XR under Generic Law 9.787/1999.
You must be logged in to post a comment.